Major Setback for Aeterna Zentaris - Analyst Blog

By
A A A

Aeterna Zentaris Inc. ( AEZS ) recently received a setback when an independent Data Safety Monitoring Board (DSMB) recommended the discontinuation of a phase III study on its oncology candidate perifosine. The study was evaluating the efficacy and safety of perifosine in combination with Takeda Pharmaceutical Company Limited's ( TKPYY ) Velcade (bortezomib) and dexamethasone versus placebo in relapsed or relapsed/refractory multiple myeloma patients.

The independent DSMB recommended the discontinuation of the phase III study as there was very little chance of the study meeting its primary endpoint and achieving significant progression free survival. However, the DSMB did not raise any safety concerns related to the use of perifosine

Perifosine enjoys an orphan drug designation in both the US and the EU for the treatment of multiple myeloma. The US Food and Drug Administration has also granted the candidate a fast track status.

Perifosine is also being evaluated for multiple oncology indications including renal cell carcinoma (phase II), non-small cell lung cancer (phase II), breast cancer (phase II) and neuroblastoma (phase I). 

We note that the discontinuation of the phase III study evaluating perifosine for relapsed or relapsed/refractory multiple myeloma is a huge disappointment for Aeterna Zentaris. The study was being conducted under FDA's Special Protocol Assessment program. Aeterna Zentaris had planned regulatory submission based on the potential data from the study.

Aeterna Zentaris currently carries a Zacks Rank #3 (Hold). Stocks that currently look attractive in the pharma space include companies like Cytokinetics, Inc. ( CYTK ) and Osiris Therapeutics, Inc. ( OSIR ) with a Zacks Rank #1 (Strong Buy).



AETERNA ZENTARS (AEZS): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

OSIRIS THERAPTC (OSIR): Free Stock Analysis Report

TAKEDA PHARMACT (TKPYY): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AEZS , CYTK , OSIR , TKPYY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

Most Active by Volume

71,750,472
  • $16.815 ▼ 1.38%
56,817,865
  • $13.28 ▼ 6.41%
48,389,982
  • $76.195 ▼ 3.60%
46,324,607
  • $14.585 ▼ 1.39%
45,860,060
  • $3.42 ▼ 2.01%
45,504,390
  • $97.015 ▼ 1.80%
41,734,697
  • $98.98 ▼ 1.76%
35,773,568
  • $25.04 ▼ 0.52%
As of 10/1/2014, 03:25 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com